Figure 8.

A) Purification of pLDH with Ni-NTA agarose affinity chromatography. Lane M, molecular weight protein marker; lane 1, induced E. coli DH5α cell lysate with IPTG; lane 2, flow-through; lane 3, wash; lane 4–5, elutes. B) Western blot analysis of pLDH recombinant protein. a, Malaria patients; b, Healthy individuals. C) Scattergram of absorbances measured by ELISA using pLDH recombinant protein. Sera from healthy individuals and malaria patients infected with P. vivax were used. Cut off showed the mean + 2 X SD of negative controls.